GENELUX Corp
Close on Oct 19, 2026
- Market cap
- $110.15M
- P/E (TTM)
- –
- Dividend yield
- –
About Genelux
Pharmaceutical Preparations, SIC 2834
Genelux Corporation is a late clinical-stage biopharmaceutical company focused on developing next-generation oncolytic viral immunotherapies. The company designs off-the-shelf personalized treatments engineered to selectively destroy cancer cells and stimulate an immune response targeting unique tumor neoantigens. Its proprietary selection and development platform, CHOICE, leverages engineered strains of the vaccinia virus to establish an extensive library of product candidates. Its primary clinical candidate, Olvi-Vec, is evaluated across monotherapy and combination settings for patients with aggressive, difficult-to-treat solid tumors who have experienced limited success with conventional standards of care.
The company operates a current Good Manufacturing Practice facility located in San Diego, California, where it manufactures clinical supply and prepares for commercial scale. Genelux also leases an additional building at the San Diego site for research laboratories and administrative functions, while maintaining clinical partnerships in China. Genelux Corporation is headquartered in Westlake Village, California.
Summary of the business section of Genelux's latest annual report, written by StockData.
Company profile
Company
- Legal name
- GENELUX Corp
- Headquarters
- Westlake Village, CA
- Address
- 2625 Townsgate Road, Suite 230 91361
- Phone
- (805) 267-9889
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Weinberg & Company, P.A., Los Angeles, California
Stock & identifiers
- Ticker
- GNLX
- Exchange
- Nasdaq
- IPO date
- Jan 26, 2023
- Shares outstanding
- 45M, Aug 11, 2026
- Public float
- $89.10M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- SEC CIK
- 1231457
- CUSIP
- 36870H103
- ISIN
- US36870H1032
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Yong Yu | Chief Scientific Officer | 258,688 |
| Thomas Zindrick | President and CEO | 1,426,427 |
| Joseph Cappello | Chief Technical Officer | 318,480 |
| Eric Groen | General Counsel | 233,957 |
| Matthew Pulisic | Chief Financial Officer | 278,906 |
| Ralph Smalling | Head of Regulatory | 67,611 |
| Jason Litten | Chief Medical Officer | – |
| Sean Ryder | General Counsel | 47,621 |
| Lourie S. Zak | Chief Financial Officer | 82,452 |
| John W. Smither | Director | 91,403 |
| Mary Mirabelli | Director | 102,693 |
| John Thomas | Director | 501,193 |
| James L. Tyree | Director | 96,483 |
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jul 14, 2023 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jan 26, 2023 | IPO | Initial public offering priced (424B4 prospectus) |
| Jan 23, 2023 | Listing | Registration of securities on an exchange (Form 8-A) |